J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding

Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offer advantages over Vabysmo, a Roche drug approved for wet age-related macular degeneration and diabetic macular edema.

The post J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding appeared first on MedCity News.

Leave a Reply

Your email address will not be published. Required fields are marked *